CVS Health is launching Health100, an AI-enabled health platform developed with Google Cloud to consolidate data from multiple sources and support real-time health management for customers.

Waystar is pushing agentic AI that can autonomously decide and act within revenue cycle workflows, moving beyond automation toward self-learning capabilities.

The mobile app accompanying Health100 will offer AI-driven experiences via visual and voice interactions to improve access to care and help reduce out-of-pocket costs.

Waystar reported its fourth-quarter and full-year 2025 results, along with guidance for 2026 and earnings expectations from analysts and banks regarding Waystar stock targets.

Valuation signals for CVS are mixed, with a high P/E around 57.8, a P/S near 0.25, P/B about 1.35, and a cautious but optimistic sentiment with a target price near 93.75 and substantial institutional ownership.

The release includes forward-looking statements and notes that projections are subject to change based on current management expectations and risks.

The report originates from Reuters and is summarized via FAST on Channel NewsAsia, inviting readers to view the full article.

Waystar’s press materials emphasize its vast data assets and the vision of an autonomous revenue cycle that removes friction in real-time while continuously learning from outcomes.

Waystar positions itself as providing mission-critical infrastructure for healthcare payments to improve outcomes through autonomous revenue-cycle capabilities.

Waystar highlights substantial early outcomes, including preventing over $15 billion in denied claims and cutting denial appeal and recovery time by around 90%, with AI embedded in workflows.

The AltitudeAI platform is cited as having prevented more than $15 billion in denied claims and delivering about a 90% reduction in denial processing time in under a year.

Market reaction to the CVS-Waystar developments has been mixed, with CVS stock dipping as investors weigh AI potential against broader market factors.